Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 24 Apr 2023
Canada: The Journal of Psychiatric Research recently reported that childhood cat ownership, particularly with rodent-hunting cats,.
Read Full NewsHigher vs lower nighttime light exposure is associated with increased risk for obesity, hypertension, and dyslipidemia in patients with schizophrenia, a study suggests.
Transperineal 3D mapping biopsy may help select patients with low-risk prostate cancer who are most likely to fare well with active surveillance.
Many experts consider prostate cancer one of immunotherapy’s biggest disappointments. But a handful of patients don’t fit that narrative, and researchers are starting to uncover why.
1.
FDA Leaders Explain Their Choice Regarding Cancer Risk Warning in CAR-T Investigation.
2.
Triplet Could Become a New Standard in Tough-to-Treat CLL
3.
FDA Says First 'Real-Time' Clinical Trial Is Underway
4.
'Sleep ALL night' program helps children with leukemia sleep better during treatment
5.
PSMA PET Beats MRI in Prostate Cancer Staging Study
1.
The Role of the Oncology Pharmacist: From Treatment to Trials and Beyond
2.
Biologic Therapies for Cutaneous Immune-Related Adverse Events in the Era of Immune Checkpoint Inhibitors
3.
Case Study: Combining Targeted Therapy with Immunotherapy for Metastatic Melanoma
4.
A Comprehensive Guide to Living with Cutaneous T Cell Lymphoma: Tips & Strategies
5.
The Importance of Understanding Your D-Dimer Levels: A Comprehensive Guide
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
2.
Virtual Case Study on Pedal Edema and Triple Vessel Disease - An Initiative by Hidoc Dr.
3.
Should We Use DARA Up Front As First-Line Therapy in MM?
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part IV
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge